Community Health Trades at a Deep Discount to Peers: Hold or Fold?

Community Health Systems, Inc. price-consensus-eps-surprise-chart | Community Health Systems, Inc. Quote

Growth Drivers

CYH is continuing to invest in its existing markets through targeted acquisitions. In the second quarter of 2026, it completed the majority-stake acquisitions of Surgical Institute of Alabama and South Anchorage Surgery Center. As per management, these acquisitions are strengthening CYH's positions in core markets and meeting expectations for operating and financial performance. Expanding within established markets could strengthen physician relationships, broaden service capabilities, and create opportunities for incremental revenue growth.

CYH is benefiting from higher reimbursement rates and newly approved Medicaid state-directed payment programs. The Florida and Indiana programs contributed approximately $40-$45 million to its second-quarter 2026 EBITDA, including $20-$25 million related to prior periods. These additional payments helped offset some of the pressure from unfavorable payer and service mix. Higher reimbursement rates and supplemental Medicaid payments can support revenue and EBITDA growth, providing an important earnings tailwind for CYH.

The company continues to focus on operating efficiency while reshaping its portfolio. Same-store operating expense per adjusted admission increased only 0.3% in the second quarter of 2026, while contract labor spending declined 5.6% and supplies expense fell 70 basis points to 14.2%. CYH also used approximately $600 million of divestiture proceeds to repurchase debt. Total operating expenses declined 6.8% year over year in the first half of 2026. Long-term debt amounted to approximately $9.6 billion, down from $10.4 billion as of year-end 2025. Continued cost discipline could support EBITDA stabilization, while debt reduction could reduce financial pressure and improve financial flexibility.

CYH: Key Risks

Community Health continues to face financial and operational pressures. Adjusted EBITDA declined to $330 million from $380 million a year ago, while unfavorable payer and service mix, higher uncompensated care and continued softness in elective procedures weighed on margins. Medical specialist fees also increased 19% year over year on a same-store basis, adding to cost pressures.

CYH also faces pressure on cash generation. It used $209 million of cash in operating activities in the first half of 2026 compared to $208 million cash generated from operating activities in the prior-year period. Although operating cash flow improved to $87 million in second-quarter 2026, the company lowered its 2026 operating cash flow guidance to $300-$500 million from $600-$700 million. Continued operating pressures and cash-flow volatility could limit financial flexibility and slow progress toward sustained free cash flow generation.

Top-Ranked Players

Some better-ranked stocks in the broader Medical space areTenet Healthcare Corporation (THC), BrightSpring Health Services, Inc. BTSG and Surgery Partners, Inc. SGRY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $20.16 per share, indicating a 20.1% year-over-year improvement. THC beat earnings estimates in each of the trailing four quarters, with the average surprise being 22.7%. The consensus estimate for 2026 revenues is pinned at $22.17 billion, implying 4% year-over-year growth.

The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.78 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for 2026 revenues is pinned at $15.24 billion, implying 18.1% year-over-year growth.

The Zacks Consensus Estimate for Surgery Partners’ 2026 earnings is pegged at 42 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. SGRY beat earnings estimates in two of the trailing four quarters and missed in the other two, with the average surprise being 96.78%. The consensus estimate for 2026 revenues is pinned at $3.43 billion.